top of page
Search

Guardant (GH): Start of a new product cycle

  • Writer: Abacus Research
    Abacus Research
  • Sep 17, 2025
  • 1 min read

Guardant Health is a leader in liquid biopsy, a blood test, for cancer profiling and now screening.


Guardant has two new liquid biopsy products that look to be ramping fast and are well positioned. There is a massive TAM to go after, >>$100bn vs Industry revenues of ~$3-5bn.

  • Shield, one of the new products, could be the start of a very big thing for GH, and Q2 2025 showed very encouraging momentum.


We believe that Shield could make the company: revenues could increase from $60m this year to $700m in 2028 with potential upside if Shield becomes a multi-cancer screening platform. In our opinion Guardant has a meaningful first mover advantage, it just needs to prove commercial execution.


Potential Upside: $150 (+170%) over 3 years

Sensible Downside: $23(-50%)


 
 
 

Recent Posts

See All
Axon:

Axon is shifting from selling individual tools to providing an interconnected ecosystem. Hardware like TASERs and cameras now act as "data generators" that feed directly into high-margin software modu

 
 
 
C.H. Robinson

CHRW has been going through significant change, They are retaking market share. The new CEO has transformed the company by bringing in a lean / AI, that has helped CHRW to grow earnings despite strugg

 
 
 
Brookfield (BN):

We initially wrote up BN in Jan 2024, it has increased 70%, so why mention it again? Firstly, we think the fundamentals are as good now as they were 2 yrs ago, with a >15% IRR on offer. BN is not a we

 
 
 

Comments

bottom of page